Irinotecan in 5-fluorouracil-refractory colorectal cancer.
Danesi
Romano
R
Division of Pharmacology and Chemotherapy, Department of Oncology, University of Pisa, Italy.
Di Paolo
Antonello
A
D000328:Adult; D000368:Aged; D002166:Camptothecin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D005472:Fluorouracil; D006801:Humans; D007262:Infusions, Intravenous; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010166:Palliative Care / Q000379:methods*; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D016896:Treatment Outcome
D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin